Southern Africa out of control Swaziland South Africa Namibia Botswana Zimbabwe Lesotho Zambia 19902007 400 800 1200.

Slides:



Advertisements
Similar presentations
Research activities in Orange Farm Bertran Auvert INSERM University of Versailles, France Country update meeting on scaling - up of male circumcision programmes.
Advertisements

Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.
Draft Generic Protocol: Measuring Impact and Effectiveness of National Programs for Prevention of Mother-To-Child HIV Transmission at Population-Level.
Referral of participants for HIV follow-up care Africa Centre MDP experiences Presented by: Hlengiwe Ndlovu MDP Clinic coordinator.
NATIONAL INSTITUTES OF HEALTH: National Institute of Allergy and Infectious Diseases National Institute of Mental Health National Institute on Drug Abuse.
Version 11Page 1 of 6 Improving Identification of Patients Infected with HIV Using Rapid Testing in the Emergency Department: A Systems-Based Approach.
Effectiveness of the National PMTCT Program in Rwanda
Washington D.C., USA, July 2012www.aids2012.org The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare L. Mupfumi.
W: Supported by Epidemiology of sub-patent Plasmodium falciparum infection: implications for detection of hotspots.
Tathmini GBV: Evaluating Comprehensive Gender-Based Violence Program Scale-up in Tanzania Susan Settergren Futures Group.
Sensitivity, specificity and predictive values of symptoms to detect tuberculosis in the ZAMSTAR community based prevalence studies Peter Godfrey-Faussett.
National TB/ Leprosy Programme Manager
ZAMSTAR - the Zambian South African TB and AIDS Reduction trial ZAMBART, UNZA Desmond Tutu TB Centre, Univ Stellenbosch CBOH, Zambia LDHMT, Zambia Prov.
Accelerating TB/HIV activities in Zambia Alwyn Mwinga 2007 HIV Implementers Meeting 20 June 2007.
Molecular methods for TB drug resistance testing: what is needed? Experience from Khayelitsha, Cape Town, South Africa Helen Cox, PhD, Burnet Institute.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Challenge 4: Linking TB & HIV/AIDS Programs Kayt Erdahl, Project HOPE Rodrick Nalikungwi, Project HOPE Malawi December 18, 2008.
Treatment as prevention: a new paradigm for HIV control? Richard Hayes.
Making it happen! In Support of the Global Plan Towards the Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive.
CAPRISA is the UNAIDS Collaborating Centre for HIV Research and Policy Impact of conditional cash incentives on HSV-2 and HIV in rural high school students.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
PREVALENCE OF ANAEMIA IN WOMEN AT SCREENING AND FOLLOW-UP IN A MICROBICIDE PHASE III TRIAL Hasinah Asmal, Dinesh Singh, Gita Ramjee HIV Prevention Research.
FHI’s Global ART Program: Today's snapshot and tomorrow's vision 10 August 2010 Kwasi Torpey, MD, PhD, MPH Regional Senior Technical Advisor, FHI 8 th.
Quality of Care at a Multi-site PEPFAR-funded ART Program: From Measuring to Improvement.
ICAP Quarterly Master Slide Set April-June Site Census What: Ongoing, real-time inventory of all planned, current, and closed ICAP sites. Supported.
Zambia National Malaria Indicator Survey (MIS) 2010 Welcome!! The Barn Motel Lusaka.
Informed Consent in a Community Based Tuberculosis Prevention Study in the Western Cape, South Africa Prof Keymanthri Moodley, Prof Nulda Beyers,, Dr Sharon.
STD Surveillance Network (SSuN) Cycle 2 Objectives Lori Newman & Kristen Mahle SSuN Principal Collaborators Meeting Atlanta, GA December 2, 2008.
Scaling-up male circumcision programmes in the Eastern and Southern Africa Region Country update meeting HIV Testing and Counseling and Male Circumcision.
UNITED STATES CONFERENCE ON AIDS MONDAY, SEPTEMBER 9, 2013 NEW ORLEANS, LA Will Community Involvement in Test Link to Care, Plus Treat Research (HPTN 065)
ICAP Track 1.0 Year 6: Reaching Targets Focus on Quality Continued Innovations David Hoos, MD, MPH Dar es Salaam August 4, 2009.
Orphans and other Vulnerable Children: Scaling up Responses Moderator:Mr. Perry Mwangala, USAID Zambia Presenters:Stan Phiri, UNICEF East and Southern.
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
TB prevention: new data, new approaches, new challenges Improving health worldwide Alison Grant London School of Hygiene & Tropical Medicine.
Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-
Effect of community-wide isoniazid preventive therapy on tuberculosis among South African gold miners “Thibelo TB” Aurum Health Research LSHTM JHU Gold.
ZAMSTAR  24 communities in 2 countries  > 1million people  Embedded in the health systems of the 2 countries  Study end point will be prevalence surveys.
Background Methods Use of free to use social media to disseminate information in healthcare has increased, but evidence of the effect of this effort is.
Data Management ZAMSTAR: from preparation to using it … Year 3: Kathy, Nkatya, Ab ZAMSTAR.
Distribution of Number of People Infected with HIV Total = 10.7 million in 2000.
Thibela TB Trisha Crawford James Lewis Katherine Fielding.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
Early TB case detection in pre-trial detention centers (SIZOs) and prison colonies in Ukraine 46 th Union World Conference on Lung Health Cape Town, South.
COSTS STUDY OF SEVERE PNEUMONIA IN AN EQUIVALENCE TRIAL OF ORAL AMOXICILLIN VERSUS INJECTABLE PENICILLIN IN CHILDREN AGED 3 TO 59 MONTHS Patel AB, APPIS.
Integrated Community HIV Testing Campaigns: Leveraging HIV infrastructure for non- communicable diseases July 23, 2012 Gabriel Chamie, Dalsone Kwarisiima,
ZAMSTAR restricted randomisation CREATE Investigators Meeting 2005 Charalambos (Babis) Sismanidis LSHTM.
SAFETY AND EFFICACY OF MVA85A, A NEW TUBERCULOSIS VACCINE, IN INFANTS PREVIOUSLY VACCINATED WITH BCG: A RANDOMISED, PLACEBO-CONTROLLED PHASE 2B TRIAL Michele.
Janet Heitgerd, PhD Program Evaluation Branch, Associate Chief for Science American Evaluation Association Annual Meeting November 2010 Improving the Design,
Increasing Tuberculosis Prevalence in South African Township Associated With Increasing HIV Prevalence Slideset on: Lawn SD, Bekker LG, Middelkoop K, Myer.
Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,
HPTN 071 (PopART): Have we reached the targets after two years of the PopART intervention IAS Paris July 2017 Richard Hayes.
Durban, July 20th 2016 Ruggero Giuliani MSF - Mozambique
Gaps in the cascade of care in two high prevalence settings in Zimbabwe and Malawi Nolwenn Conan1, Cyrus Paye2, Erica Simons2, Abraham Mapfumo3, Tsitsi.
Charles D. Wells, MD Chief, International Research and Programs Branch
Facilitating development and adaptation of the right tools
Conclusions Background Results Acknowledgements: Methods
Getting to the second 90 in adolescent HIV: What is needed
Richard hayes London school of hygiene & Tropical Medicine
Katharina Hauck On behalf of the HPTN 071 Study Team
World Health Organization
Measuring progress against targets in Zambia using routine data collected by community health workers: HPTN 071 (PopART) trial Kwame Shanaube.
Prevention Now for Women!
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
C R E A E Consortium to Respond Effectively to the AIDS-TB Epidemic
From trials to programmes: Lessons learned from four trials of Universal Testing and Treatment (UTT) in Sub-Saharan Africa 24th July 2018 Estimates of.
From ProTEST to Nationwide Implementation
Multi-disease diagnostic integration
DSD and TB/HIV services in Zimbabwe
Kenneth Sherr Embedded implementation science to enhance the relevance of effectiveness trials for structural interventions Kenneth Sherr.
Presentation transcript:

Southern Africa out of control Swaziland South Africa Namibia Botswana Zimbabwe Lesotho Zambia

P. Godfrey-Faussett, H. Ayles, N. Beyers Southern Africa Map Source: Google Earth October 2007 Zambia Western Cape 0 30 Km 15 Zambia Km 200 A community randomized trial of two interventions delivered to ~1,000,000 people while strengthening the existing health systems

Enhanced Case finding (ECF)  Community Mobilization and sputum collection  School intervention  Open Access at the clinic  Guiding Principles ▪Every person able to give sputum within 30 min walk ▪Sputum smear results within 48 hours

Household Intervention (HH)  Using a TB patient as the Gateway to a household at risk of TB and HIV  3 visits (0,2, completion TB treatment)  Group education TB/HIV  TB screening  HIV testing (group, couple, individual)  Counselling and referral for care

Actual Trial  Total Population 962,655  6 communities per arm  Primary endpoint:  Prevalence of TB ●Enhanced case finding (ECF) Vs no ECF ●Household Intervention (HH) Vs no HH  Secondary Endpoint :  Community level: TB transmission TB/HIV at the clinic: 257,698 Enhanced Case Finding: 148,090 Household: 257,729 ECF & Household: 299,138

Prevalence surveys  Random sample of adults living in each of 24 communities  Geographically based clustered sample used  Every adult equal chance of being picked  Respiratory sample collected from every consenting adult and cultured on MGIT

Household enumerated 48,395 Eligible Individuals 123,790 No consent from household 7,055 Individual Consent 90,601 QuestionnaireRespiratory sample Individuals not found or no consent 33,189 Household visited 55,450 HIV test, blood sugar Field work Flow

Laboratory methods  Sample receipt  Samples transported to 5 laboratories (furthest site 800 km)  Each sample inoculated on two manual MGIT tubes ●Reduce proportion of contaminated samples ●Increase yield  QA: Each batch of samples processed with one positive and negative control  Each laboratory working at maximum capacity (100 per day in each mini-lab, 200 per day in centralised lab)  Isolate identification  ZN stain  MPB 64 Ag test  16s rRNA gene sequencing done on samples that were either ZN stain positive or MPB64 positive

Evaluable Culture 64,430 M.tb (16S) 884 No TB 63,546 Both cultures Contaminated 9,461 Consented 90,601 Batch rejected due to QA failure 16,710 Laboratory Flow

Prevalence of TB  Zambian sites ▪Prevalence 542/100,000 adults (SD 263) ▪Community range 221-1,096/100,000  South African sites ▪Prevalence 2,319/100,000 adults (SD 487) ▪Community range /100,000

clinic 770/100,000 (ref) ECF 1,010/100,000 aRR 1.03 [ ] Household 700/100,000 aRR 0.77 [ ] ECF & Household 880/100,000 aRR 0.89 [ ]

clinic ECF Household ECF & Household Prevalence 880/100,00 (Ref) Prevalence 780/100,000 Adj RR 0.82 ( ) P=0.07

clinic ECF Household ECF & Household Prevalence 730/100,00 (Ref) Prevalence 940/100,000 Adj RR 1.09 ( ) P=0.48

Transmission endpoint  Longitudinal design  Direct measure of incidence of tuberculous infection  Follow children TST negative at baseline and measure rate of TST conversion  Advantage over repeated cross sectional design in that cumulative incidence would be acquired throughout child’s life and not just for the duration of the interventions  Trial outcome, so favour specificity over sensitivity

2 nd TST Survey results  12,075 children seen, assented, injected and read at 2 nd survey.  8809 negative at baseline.  Median follow-up period was 4 years (IQR: ).

TST conversion rate (per 100 person-years) against baseline prevalence of TB infection in 6-11 year olds

Summary  Community randomized trial conducted in 24 communities in Zambia and Western Cape SA  Great need for interventions to reduce TB and HIV  HH intervention reduced the prevalence of culture positive TB by 18%  HH intervention also associated with an important reduction in incidence of tuberculous infection in children  No effect seen from ECF intervention

Future Directions  ZAMSTAR has built a huge team involving researchers, communities and health systems  Platform for the PopART (HPTN 071) study  Builds on ZAMSTAR household counselling intervention to deliver universal coverage of combination prevention and test and treat

Lessons for impact evaluations  Heterogeneity of communities ▪Opportunity for interventions ▪Challenge for trial design ▪TB>HIV  Herd effects ▪TB and HIV intervention trials need to be huge ▪Need to understand transmission networks  HIV incidence similar to TB incidence rates ▪TB and HIV intervention trials need to be huge

 ZAMSTAR Team; Communities; Participants; Zambian Ministry of Health; Western Cape Provincial and South African National Department of Heath; CREATE; Bill and Melinda Gates Foundation (Grant No )